For a stretch of time, "compounded GLP-1" was one of the most searched phrases in the metabolic-health world, and for a very specific reason. When demand for the brand-name medicines outstripped supply, the resulting shortages opened a particular, temporary path for compounding pharmacies to help fill the gap. Now that the shortage period has wound down, a lot of patients and brands are confused about what changed, what compounding actually is, and what is and is not allowed. As a compounding pharmacist, let me clear up some of the fog.
What compounding actually means
First, let us define the term, because it is widely misunderstood. Compounding is the practice of a licensed pharmacy preparing a medication tailored to a specific patient's needs, typically based on a prescription. It is a legitimate, long-standing part of pharmacy practice, used for things like adjusting a dose, removing an allergen, or creating a form a patient can actually take.
Compounded medications are not FDA-approved products in the way brand-name drugs are. That is not a scandal; it is simply how compounding works. Approved drugs go through the full approval process as finished products, while compounded preparations are made by pharmacies under a different regulatory framework, with their own rules and oversight. The distinction matters enormously for what follows.
Why the shortage changed the rules temporarily
Under normal circumstances, there are meaningful limits on compounding copies of commercially available, approved drugs. But regulations include provisions that come into play when an approved drug is in official shortage. During those periods, compounders can, within specific conditions, prepare versions to help meet patient need when the approved product simply is not available.
That is the window that opened during the GLP-1 shortages. It was never a permanent free-for-all. It was a shortage-linked accommodation, contingent on the drugs remaining in short supply.
The key thing to understand is that this pathway was always tied to the shortage itself. When the shortage status changes, the conditions that permitted widespread compounding change with it.
What the end of the shortage reshapes
As the official shortage situation resolved, the special conditions that had enabled broad compounding of these medicines narrowed. In general terms, once an approved product is no longer considered in shortage, the latitude to compound copies of it tightens considerably. This does not erase compounding from the picture entirely, but it changes access substantially, and it means that arrangements which were permissible during the shortage may no longer be.
I am deliberately keeping the regulatory specifics general here, because the details have evolved through transition periods and continue to be governed by agency guidance and state pharmacy rules. The honest, accurate takeaway is directional: the post-shortage environment is more restrictive than the shortage environment was, and anyone operating in this space needs current, qualified guidance rather than assumptions carried over from the shortage era.
What patients and brands should take away
For patients, the core message is simple. Whether a medicine is brand-name or compounded, it should reach you through a legitimate, licensed pathway with a real prescription and clinical oversight. The proliferation of the shortage period also drew in less scrupulous actors, and the gray market, unregulated sellers offering "GLP-1" with no pharmacy, no prescriber, and no accountability, is a genuine danger to avoid entirely.
For brands considering this category, the lesson is about doing homework and staying current. The compliance landscape is not static, and building on shortage-era assumptions is a risk. The responsible model is one grounded in licensed physicians, legitimate pharmacies, and adherence to applicable federal and state requirements. Compounding has a real and valuable place in medicine. But its role with GLP-1s specifically is defined by a regulatory framework that shifted when the shortage ended, and respecting that framework is not optional. It is the whole point.